Seven Fleet Capital Management LP Raises Position in Assembly Biosciences, Inc. $ASMB

Key Points

• Seven Fleet Capital Management increased its Assembly Biosciences position by 671.5% in the second quarter, acquiring 377,000 additional shares for a total of 433,147 shares valued at approximately $11.9 million.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $44.00, although ratings range from “Strong Buy” to “Sell.”
• Assembly Biosciences reported a quarterly loss of $0.20 per share, beating estimates for a $0.72 loss, while revenue of $13.37 million exceeded the $8.60 million consensus forecast.

Seven Fleet Capital Management LP lifted its holdings in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) by 671.5% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 433,147 shares of the biopharmaceutical company's stock after buying an additional 377,000 shares during the period. Assembly Biosciences comprises about 2.0% of Seven Fleet Capital Management LP's portfolio, making the stock its 10th biggest holding. Seven Fleet Capital Management LP owned about 2.13% of Assembly Biosciences worth $11,903,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Informed Momentum Co LLC grew its position in Assembly Biosciences by 1.6% in the fourth quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company's stock valued at $1,004,000 after acquiring an additional 451 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in Assembly Biosciences by 4.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company's stock worth $672,000 after acquiring an additional 800 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Assembly Biosciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company's stock worth $4,468,000 after acquiring an additional 1,212 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Assembly Biosciences by 4.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company's stock worth $1,095,000 after acquiring an additional 1,634 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 3,319 shares during the last quarter. 19.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the company an "outperform" rating in a report on Monday, June 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Guggenheim restated a "buy" rating and issued a $43.00 target price on shares of Assembly Biosciences in a research report on Thursday, May 28th. Wall Street Zen lowered shares of Assembly Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $44.00.

Assembly Biosciences Trading Up 0.3%

NASDAQ:ASMB opened at $35.42 on Thursday. The stock has a market cap of $721.15 million, a P/E ratio of 34.73 and a beta of 1.10. The stock's 50-day moving average is $27.81 and its 200-day moving average is $27.79. Assembly Biosciences, Inc. has a 1-year low of $20.23 and a 1-year high of $39.71.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The business had revenue of $13.37 million during the quarter, compared to analyst estimates of $8.60 million. As a group, equities analysts forecast that Assembly Biosciences, Inc. will post 2.28 EPS for the current year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.